Related Experiment Videos
Antileukemic properties of organoplatinum complexes
Journal of the National Cancer Institute
|October 11, 1976
Summary
Researchers explored platinum compounds for leukemia treatment. Some compounds showed significant antitumor effects, and modifications improved solubility while maintaining activity, leading to high cure rates when combined with cyclophosphamide.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Platinum-based drugs are crucial in cancer chemotherapy.
- Developing novel platinum congeners with improved properties is an ongoing research area.
- L1210 leukemia serves as a standard model for evaluating antileukemic agents.
Purpose of the Study:
- To evaluate the antitumor activity of cis-amineplatinum congeners against L1210 leukemia.
- To identify platinum compounds with enhanced aqueous solubility and retained antileukemic efficacy.
- To investigate potential synergistic effects with cyclophosphamide.
Main Methods:
- Screening of 46 cis-amineplatinum congeners in a murine L1210 leukemia model.
- Systematic substitution of chloride anions in an optimal platinum compound with various organic and inorganic anions.
- Assessment of lifespan prolongation and synergistic activity with cyclophosphamide.
Main Results:
- Several cis-amineplatinum compounds demonstrated significant lifespan extension in tumor-bearing mice.
- Substitution of chlorides improved aqueous solubility without compromising antileukemic activity.
- Combinations of active platinum compounds with cyclophosphamide achieved up to 80% cure rates.
Conclusions:
- The evaluated cis-amineplatinum congeners represent a promising class of antileukemic agents.
- Structural modifications can enhance the therapeutic profile of platinum-based drugs.
- Combination therapy with cyclophosphamide offers a potent strategy for treating L1210 leukemia.